Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cabergoline for symptomatic adenomyosis
IRCT20110409006152N3Phase 3Completed
- Sponsor
- Kurdistan University of Medical Sciences
- Start
- Dec 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in adenomyosis comparing Cabergoline with Placebo (2 arms). Primary endpoints: Severity of dysmenorrhea, Amount of menorrhagia and 6 more. Started Dec 2025; status: completed.
02
Drugs
cabergoline
03
Conditions
adenomyosis
Beyond the preview
Go deeper on IRCT20110409006152N3.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20110409006152N3.